Abstract:Introduction: Silybin (SLB) as an effective hepatoprotective phytomedicine has been limited by its hydrophobicity, poor bioavailability and accumulation at lesion sites. Additionally, present drug loading methods are impeded by their low drug loading capacity, potential hazard of materials and poor therapeutic effects. Consequently, there is a pressing need to devise an innovative approach for preparing nanosuspensions loaded with both SLB and Silybin Meglumine salt (SLB-M), as well as to investigate the therapeutic effects of SLB nanosuspensions against hepatic fibrosis.Methods: The SLB nanosuspension (NS-SLB) was prepared and further modified with a hyaluronic acid-cholesterol conjugate (NSSLB-HC) to improve the CD44 targeting proficiency of NS-SLB. To validate the accumulation of CD44 and ensure minimal cytotoxicity, cellular uptake and cytotoxicity assessments were carried out for the nanosuspensions. Western blotting was employed to evaluate the anti-hepatic fibrosis efficacy in LX-2 cells by inhibiting the secretion of collagen I. Hepatic fibrosis mouse models were used to further confirm the effectiveness of NS-SLB and NS-SLB-HC against hepatic fibrosis in vivo.Results: Uniform nanosuspensions were prepared through self-assembly, achieving high drug loading rates of 89.44% and 60.67%, respectively. Both SLB nanosuspensions showed minimal cytotoxicity in cellular environments and mitigated hepatic fibrosis in vitro. NS-SLB-HC was demonstrated to target activated hepatic stellate cells by receptor-ligand interaction between HA and CD44. They can reverse hepatic fibrosis in vivo by downregulating TGF-beta and inhibiting the secretion of alpha-SMA and collagen I.Conclusion: Designed as a medical excipient analogue, SLB-M was aimed to establish an innovative nanosuspension preparation method, characterized by high drug loading capacity and a notable impact against hepatic fibrosis.

In vivo fate of lipid-silybin conjugate nanoparticles: Implications on enhanced oral bioavailability.

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

In Vivo Fate of Biomimetic Mixed Micelles As Nanocarriers for Bioavailability Enhancement of Lipid-Drug Conjugates.

Nanostructured Lipid Carriers for Parenteral Delivery of Silybin: Biodistribution and Pharmacokinetic Studies.

Comparison of the Oral Bioavailability of Silymarin-Loaded Lipid Nanoparticles with Their Artificial Lipolysate Counterparts: Implications on the Contribution of Integral Structure.

[Study on the Preparation and Bio-Distribution of Silybin Lipid Nanospheres].

Solid Lipid Nanoparticles and Chitosan-coated Solid Lipid Nanoparticles as Promising Tool for Silybin Delivery: Formulation, Characterization, and In vitro Evaluation

Silybin Meglumine-Stabilized Nanosuspension Enhances the Therapeutic Efficacy of Silybin Against Hepatic Fibrosis

Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD

Supersaturated polymeric micelles for oral silybin delivery: the role of the Soluplus-PVPVA complex

The Efficiency and Mechanism of N-octyl-O, N-carboxymethyl Chitosan-Based Micelles to Enhance the Oral Absorption of Silybin

Preparation and Characterization of Silybin-Loaded Nanostructured Lipid Carriers

<i>In vitro</i>and<i>in vivo</i>evaluation of silybin nanosuspensions for oral and intravenous delivery

Combined Amphiphilic Silybin Meglumine Nanosuspension Effective Against Hepatic Fibrosis in Mice Model.

Phytosome-nanosuspensions for silybin-phospholipid complex with increased bioavailability and hepatoprotection efficacy

Enhanced Bioavailability of the Poorly Water-Soluble Drug Fenofibrate by Using Liposomes Containing a Bile Salt

Silymarin Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral Bioavailability

Silymarin-Loaded Nanoparticles Based on Stearic Acid-Modified Bletilla striata Polysaccharide for Hepatic Targeting

The Pharmacokinetics and Liver-Targeting Evaluation of Silybin Liposomes Mediated by the NTCP/OCTN2 Dual Receptors

Mechanisms Of Oral Absorption Improvement For Insoluble Drugs By The Combination Of Phospholipid Complex And Snedds

Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin.